Amgen vs Regeneron Pharmaceuticals
AMGN and REGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMGN and REGN compare
Amgen is the larger company, worth 2.6 times as much as Regeneron Pharmaceuticals ($252B against $95.5B).
On earnings, Regeneron Pharmaceuticals is cheaper: it trades at 20.5× trailing earnings, against 28.9× for Amgen.
Regeneron Pharmaceuticals grew revenue faster over the last twelve months (18.6% versus 9.1% for Amgen).
Regeneron Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 28.5% compared with 23.0% at Amgen.
Both pay dividends: Amgen yields 2.1% and Regeneron Pharmaceuticals 0.40%.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMGN | REGN |
|---|---|---|
| Size and price | ||
| Market cap | $252B | $95.5B |
| Share price | $466.01 | $927.89 |
| Change, 1 year | 59.7% | 42.1% |
| Change, 5 years | 118% | 51.7% |
| Beta (5Y) | 0.42 | 0.64 |
| Employees | 32K | 15K |
| StockData Score | ||
| Total score | 17 | 17 |
| Valuation score | 0 | 1 (better) |
| Growth score | 5 (better) | 3 |
| Performance score | 6 (better) | 4 |
| Health score | 2 | 6 (better) |
| Dividend score | 4 (better) | 3 |
| Valuation | ||
| P/E | 28.9× | 20.5× (better) |
| P/S | 6.6× | 5.7× (better) |
| P/B | 21.6× | 2.9× (better) |
| EV/EBITDA | 20.9× | 16.4× (better) |
| P/FCF | 24.8× (better) | 25.0× |
| PEG | 5.24 (better) | 7.41 |
| FCF yield | 4.0% (better) | 4.0% |
| Fair value | $334.49 | $851.58 |
| Margin of safety | −39.3% | −9.0% (better) |
| Growth | ||
| Revenue growth (TTM) | 9.1% | 18.6% (better) |
| Revenue growth, 5Y average | 7.6% | 11.0% (better) |
| Net income growth (TTM) | 32.1% (better) | 5.2% |
| EPS growth (TTM) | 31.6% (better) | 8.4% |
| EPS growth, 5Y average | 2.9% | 6.3% (better) |
| Profitability | ||
| Gross margin | 69.5% | – |
| Operating margin | 30.0% (better) | 28.8% |
| Net margin | 23.0% | 28.5% (better) |
| FCF margin | 26.7% (better) | 22.6% |
| Return on equity | 91.5% (better) | 14.9% |
| Return on invested capital | 17.6% (better) | 16.3% |
| Financial health | ||
| Debt / equity | 4.90 | 0.06 (better) |
| Net debt / EBITDA | 3.07 (better) | −1.36 |
| Interest coverage | 4.3× | 104× (better) |
| Current ratio | 1.37 | 3.35 (better) |
| Altman Z-score | 2.39 | 7.64 (better) |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | 2.1% (better) | 0.40% |
| Payout ratio | 60.4% | 8.0% |
| Years of dividend growth | 9 | – |
| Dividend growth, 5Y average | 8.0% | – |
| Buyback yield | – | 2.1% |
| Shareholder yield | 2.1% | 2.5% (better) |
| Ownership | ||
| Held by institutions | 82.7% | 89.0% |
| Held by insiders | 0.21% | 3.8% |
| Insider net buying, 12 months | −$29.3M | −$8.7M (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 2.6% | 2.2% |
Go deeper
- AMGN stock overview
- AMGN income statement
- AMGN valuation and score
- REGN stock overview
- REGN income statement
- REGN valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.